Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Immune modulation via T regulatory cell enhancement : Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). / Roth-Walter, Franziska; Adcock, Ian M.; Benito-Villalvilla, Cristina; Bianchini, Rodolfo; Bjermer, Leif; Boyman, Onur; Caramori, Gaetano; Cari, Luigi; Fan Chung, Kian; Diamant, Zuzana; Eguiluz-Gracia, Ibon; Knol, Edward F.; Kolios, Antonios; Levi-Schaffer, Francesca; Nocentini, Giuseppe; Palomares, Oscar; Redegeld, Frank; Van Esch, Betty; Stellato, Cristiana.

I: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Nr. 1, 2021, s. 90-113.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Roth-Walter, F, Adcock, IM, Benito-Villalvilla, C, Bianchini, R, Bjermer, L, Boyman, O, Caramori, G, Cari, L, Fan Chung, K, Diamant, Z, Eguiluz-Gracia, I, Knol, EF, Kolios, A, Levi-Schaffer, F, Nocentini, G, Palomares, O, Redegeld, F, Van Esch, B & Stellato, C 2021, 'Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)', Allergy: European Journal of Allergy and Clinical Immunology, vol. 76, nr. 1, s. 90-113. https://doi.org/10.1111/all.14478

APA

Roth-Walter, F., Adcock, I. M., Benito-Villalvilla, C., Bianchini, R., Bjermer, L., Boyman, O., Caramori, G., Cari, L., Fan Chung, K., Diamant, Z., Eguiluz-Gracia, I., Knol, E. F., Kolios, A., Levi-Schaffer, F., Nocentini, G., Palomares, O., Redegeld, F., Van Esch, B., & Stellato, C. (2021). Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy: European Journal of Allergy and Clinical Immunology, 76(1), 90-113. https://doi.org/10.1111/all.14478

CBE

Roth-Walter F, Adcock IM, Benito-Villalvilla C, Bianchini R, Bjermer L, Boyman O, Caramori G, Cari L, Fan Chung K, Diamant Z, Eguiluz-Gracia I, Knol EF, Kolios A, Levi-Schaffer F, Nocentini G, Palomares O, Redegeld F, Van Esch B, Stellato C. 2021. Immune modulation via T regulatory cell enhancement: Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). Allergy: European Journal of Allergy and Clinical Immunology. 76(1):90-113. https://doi.org/10.1111/all.14478

MLA

Vancouver

Author

Roth-Walter, Franziska ; Adcock, Ian M. ; Benito-Villalvilla, Cristina ; Bianchini, Rodolfo ; Bjermer, Leif ; Boyman, Onur ; Caramori, Gaetano ; Cari, Luigi ; Fan Chung, Kian ; Diamant, Zuzana ; Eguiluz-Gracia, Ibon ; Knol, Edward F. ; Kolios, Antonios ; Levi-Schaffer, Francesca ; Nocentini, Giuseppe ; Palomares, Oscar ; Redegeld, Frank ; Van Esch, Betty ; Stellato, Cristiana. / Immune modulation via T regulatory cell enhancement : Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO). I: Allergy: European Journal of Allergy and Clinical Immunology. 2021 ; Vol. 76, Nr. 1. s. 90-113.

RIS

TY - JOUR

T1 - Immune modulation via T regulatory cell enhancement

T2 - Disease-modifying therapies for autoimmunity and their potential for chronic allergic and inflammatory diseases—An EAACI position paper of the Task Force on Immunopharmacology (TIPCO)

AU - Roth-Walter, Franziska

AU - Adcock, Ian M.

AU - Benito-Villalvilla, Cristina

AU - Bianchini, Rodolfo

AU - Bjermer, Leif

AU - Boyman, Onur

AU - Caramori, Gaetano

AU - Cari, Luigi

AU - Fan Chung, Kian

AU - Diamant, Zuzana

AU - Eguiluz-Gracia, Ibon

AU - Knol, Edward F.

AU - Kolios, Antonios

AU - Levi-Schaffer, Francesca

AU - Nocentini, Giuseppe

AU - Palomares, Oscar

AU - Redegeld, Frank

AU - Van Esch, Betty

AU - Stellato, Cristiana

PY - 2021

Y1 - 2021

N2 - Therapeutic advances using targeted biologicals and small-molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune, and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell–based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic, or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in nononcological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in nononcological settings such as cardiovascular disease, obesity, and chronic inflammatory disorders. After describing the general features of T cell–based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell–based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

AB - Therapeutic advances using targeted biologicals and small-molecule drugs have achieved significant success in the treatment of chronic allergic, autoimmune, and inflammatory diseases particularly for some patients with severe, treatment-resistant forms. This has been aided by improved identification of disease phenotypes. Despite these achievements, not all severe forms of chronic inflammatory and autoimmune diseases are successfully targeted, and current treatment options, besides allergen immunotherapy for selected allergic diseases, fail to change the disease course. T cell–based therapies aim to cure diseases through the selective induction of appropriate immune responses following the delivery of engineered, specific cytotoxic, or regulatory T cells (Tregs). Adoptive cell therapies (ACT) with genetically engineered T cells have revolutionized the oncology field, bringing curative treatment for leukemia and lymphoma, while therapies exploiting the suppressive functions of Tregs have been developed in nononcological settings, such as in transplantation and autoimmune diseases. ACT with Tregs are also being considered in nononcological settings such as cardiovascular disease, obesity, and chronic inflammatory disorders. After describing the general features of T cell–based approaches and current applications in autoimmune diseases, this position paper reviews the experimental models testing or supporting T cell–based approaches, especially Treg-based approaches, in severe IgE-mediated responses and chronic respiratory airway diseases, such as severe asthma and COPD. Along with an assessment of challenges and unmet needs facing the application of ACT in these settings, this article underscores the potential of ACT to offer curative options for patients with severe or treatment-resistant forms of these immune-driven disorders.

KW - adoptive cell therapies

KW - allergy

KW - autoimmunity

KW - CAR-Treg cells

KW - immunoregulation

U2 - 10.1111/all.14478

DO - 10.1111/all.14478

M3 - Article

C2 - 32593226

AN - SCOPUS:85098846922

VL - 76

SP - 90

EP - 113

JO - Allergy

JF - Allergy

SN - 1398-9995

IS - 1

ER -